--- title: "China launches its first 128-channel fully implanted brain–computer interface trial" date: 2026-10-31 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-brain-tiantan-128ch-implant-trial language: en --- # China launches its first 128-channel fully implanted brain–computer interface trial > Beijing Tiantan Hospital has opened the LEAP trial of a 128-channel implanted brain–computer interface (脑机接口) for tetraplegia — China's first multicenter study. A person who cannot move a finger below the neck imagines opening a hand. A thin film of electrodes, thinner than a hair, sits inside the brain tissue and listens. A small implanted recorder turns those signals into a cursor on a screen, then into a command the hand can learn to follow again. That scene is the target of a clinical trial that began in Beijing in mid-May 2026, and it marks a specific milestone: the first Chinese multicenter trial of a fully implanted brain–computer interface (脑机接口) system built around 128 channels. ## Key takeaways - China's first 128-channel fully implanted (全侵入式) brain–computer interface (脑机接口) trial, the LEAP study, opened at Beijing Tiantan Hospital on 18 May 2026. - The system pairs an intra-cortical flexible electrode with a fully implantable, wirelessly recharged signal recorder; electrode thickness is a fraction of a human hair. - The trial plans 32 participants with tetraplegia from spinal-cord injury, across 11 medical institutions, with a 180-day observation window. - Early goals are modest and concrete: brain-controlled cursor use, then assisted hand movement and finer finger control. - It is a research study, not an approved therapy; results on safety and efficacy are still pending. ## What "fully implanted" actually means Brain–computer interface (脑机接口) systems come in three routes: non-invasive (sensors on the scalp), semi-invasive (electrodes on or just under the protective membrane), and fully invasive (electrodes placed inside the brain tissue itself). The fully invasive route trades the highest surgical risk for the cleanest signal, because the electrode talks directly to neurons rather than listening through bone and skin. The LEAP system has two modules. One is an intra-cortical implantable flexible electrode (皮层内植入式柔性电极); the other is a highly integrated fully implantable signal acquisition device (全植入式信号采集器). They connect by a thin lead. According to Jia Wang (贾旺), the trial's coordinating investigator and a neurosurgery expert at Tiantan, the electrode is about a few tenths the diameter of a human hair and has a softness close to brain tissue — design choices meant to reduce the chronic immune response that eventually silences rigid wires. ## Who it is for, and what happens The trial targets a hard problem: tetraplegia caused by high spinal-cord injury (高位脊髓损伤), where existing rehabilitation does little for motor recovery. Participants are adults aged 18 to 60. After implantation, each person rests about a month so the electrode and brain can adapt, then trains for roughly two months to tune the decoding to that individual's brain. The study then observes each participant for 180 days, measuring electrode effectiveness, resistance changes, neural-function recovery, and psychological scales. The immediate clinical aim is narrow on purpose. Patients are first expected to achieve brain-controlled cursor movement (脑控鼠标) and, with assistive training hardware, begin hand motion — with the longer hope of finer actions such as finger flexion and extension (手指屈伸). As Jia puts it, roughly 80% of daily tasks run through the hands, so recovering hand function matters more for quality of life than flashier demonstrations. ## Why 128 channels, and why a multicenter trial Channel count is a rough proxy for how much brain activity a device can read at once. A 128-channel fully implanted system is a meaningful step up from earlier lower-count implants, and, crucially, the trial is prospective and multicenter (前瞻性、多中心), with 11 hospitals joining the study. Multicenter design matters because a single-site result can hide whether a surgical and decoding procedure generalizes across different surgical teams and patient bodies. The LEAP study is sponsored by Beijing Zhiran Medical Technology (北京智冉医疗科技有限公司) and led by Tiantan Hospital, whose president, academician Wang Yongjun (王拥军), attended the launch. The framing from the hospital is explicitly about accelerating homegrown high-throughput invasive brain–computer interface (脑机接口) toward clinical translation — not about a finished product. ## Where this sits in China's BCI push This trial is one node in a fast-moving field. In March 2026 China granted what was described as the world's first Class III registration certificate for an implantable brain–computer interface (脑机接口) medical device, a spinal-cord-injury hand-function product, and several other invasive and semi-invasive systems are in trials or special review. The LEAP study's distinct contribution is the channel count combined with a multicenter, GCP-grade protocol — the kind of evidence base regulators and payers eventually require. ## Honest limitations This is an ongoing clinical trial, not an approved treatment, and no safety or efficacy results have been reported yet. The 32-participant enrollment and 180-day window are early-phase numbers; they cannot establish long-term signal stability, adverse-event rates, or real-world function. The electrode's thinness and flexibility are described by the developer and trial leaders, not yet independently benchmarked in peer-reviewed form from this study. Participant selection (18–60, tetraplegia from spinal injury) means findings may not extend to other paralysis types. No pricing or reimbursement is involved, so cost and access questions are entirely open. Figures here come from Beijing municipal science authorities, Beijing Tiantan Hospital's own announcement, China News Service, and Science and Technology Daily; no single independent audit of the trial protocol is yet public. ## What readers can do now - If you or a family member has spinal-cord-injury tetraplegia, ask a comprehensive neurology or rehabilitation center whether brain–computer interface (脑机接口) trials are recruiting — and read the eligibility criteria, not the headlines. - Treat any "paralysis cured" claim about implants with caution; look for peer-reviewed or registry results and the trial's phase. - For clinicians and engineers, the bottleneck is no longer the idea but long-term signal stability and multicenter proof — that is where careers and investment should focus. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-tiantan-128ch-implant-trial Free to quote with attribution and a link to the original.